Terminated × INDUSTRY × Squamous Cell Carcinoma of Head and Neck × Clear all A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
PEMDA-HN
Phase 2 Terminated
69 enrolled 21 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Phase NA Terminated
2 enrolled
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Phase 1/2 Terminated
95 enrolled
ELEVATE HNSCC
Phase 2 Terminated
193 enrolled 27 charts
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Phase 3 Terminated
730 enrolled 40 charts
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Phase 1 Terminated
122 enrolled
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Phase 2 Terminated
59 enrolled 18 charts
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
57 enrolled
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1 Terminated
19 enrolled
BelieveIT-201
Phase 2 Terminated
27 enrolled
STARBURST
Phase 2 Terminated
11 enrolled
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
Phase 1/2 Terminated
80 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
Phase 2 Terminated
17 enrolled
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Terminated
24 enrolled 18 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
STARLING
Phase 1 Terminated
31 enrolled
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Phase 1 Terminated
38 enrolled
Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin
Phase 1 Terminated
5 enrolled 11 charts
Study of ALE.C04 in Patients With Head and Neck Cancer
Phase 1/2 Terminated
21 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Phase 1 Terminated
64 enrolled
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases
Phase 2 Terminated
16 enrolled
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
119 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
INDUCE-4
Phase 3 Terminated
117 enrolled 33 charts
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC
Phase 1 Terminated
21 enrolled
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Phase 1 Terminated
35 enrolled
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Phase 1 Terminated
24 enrolled 29 charts
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Phase 2 Terminated
62 enrolled 24 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase 1 Terminated
14 enrolled 20 charts
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Phase 1/2 Terminated
2 enrolled
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 20 charts